11/5/2026

speaker
Marissa
Conference Call Operator

Good afternoon, ladies and gentlemen, and welcome to the Selcuity third quarter 2026 financial results call and webcast. At this time, all lines are in listen only mode. Following the presentation, we will conduct a question and answer session. If at any time during this call you require immediate assistance, please press star zero for an operator. This call is being recorded on Thursday, November 5th, 2026. and I would now like to turn the conference over to Jodi Sievers. Please go ahead.

speaker
Jodi Sievers
Investor Relations, Celcuity

Thank you, Marissa, and good afternoon, everyone. Thank you for joining us to review Salcuity's third quarter 2026 financial results and business update. Earlier today, Salcuity Inc. released financial results where the quarter ended September 30th, 2026. The press release can be found on the investor section of Salcuity's website. Joining me on the call today are Brian Sullivan, Salcuity's Chief Executive Officer and Co-Founder, Vicky Hahne, our Chief Financial Officer, as well as Igor Gorbatchevsky, our Chief Medical Officer, and Eldon Mayer, our Chief Commercial Officer, who will both be available during Q&A. Before we begin, I would like to remind listeners that our comments today include some forward-looking statements. These statements involve a number of risks and uncertainties, which are outlined in today's press release and in our reports and filings with the SEC. Actual events or results may differ materially from those projected in the forward-looking statements. Such forward-looking statements and their implications involve known and unknown risks, uncertainties, and other factors that may cause actual results or performance to differ materially from those projected. On this call, we also refer to non-GAAP financial measures. These non-GAAP measures are used by management to make strategic decisions, forecast future results, and evaluate the company's current performance. Management believes the presentation of these non-GAAP financial measures is useful for investors' understanding and assessment of the company's ongoing core operations and prospects for the future. You can find the table Reconciling the Non-Gap Financial Measures to Gap Measures in today's press release. And with that, I would like to turn the call over to Brian Sullivan, CEO of Cellcuity. Please go ahead, Brian.

speaker
Brian Sullivan
Chief Executive Officer and Co-Founder, Celcuity

Thank you, Jodi. And good afternoon, everyone. Thank you for joining our third quarter 2026 operating and financial update conference call. 2026 has been a transformative year for Cellcuity as we transition to a commercial stage company. RaptorPIC is now available to U.S. physicians to prescribe for use in combination with Silvestrin with or without palbocycline for the treatment of HR-positive, HER2-negative, locally advanced or metastatic breast cancer without a PIK3CA mutation detected following progression on or after treatment with at least one line of endocrine therapy in the metastatic setting. The unprecedented efficacy results and favorable safety profile reported from the PIK3CA wild-type cohort of the VICTORIA-1 study provide physicians with a compelling rationale to utilize a get-it-for-less regimen to address a significant unmet need for the tens of thousands of patients affected each year by advanced breast cancer. And we're pleased to report and provide our first update on the results of the foundational work our commercial and medical teams have been performing for the past two years to prepare for the commercial launch of Revtropin. Our launch is off to a great start, and results to date are all very encouraging. To provide insight into the effectiveness of our field team's launch activities, particularly since the drug became commercially available on September 30th, we can share the following key metrics. Since Revtropik became commercially available on September 30th, 78% of the top 36 strategic accounts have ordered Revtropik. These accounts treat roughly 50% of the total addressable patient population. Over 3,400 sites, many of which are affiliated with one of the top 36 strategic accounts, have directly engaged with cell acuity oncology cell specialists. These sites treat 82% of breast cancer patients. Over 1,100 healthcare providers have attended RevTropin educational programs. Our MacroAccess and medical affairs teams have also been very effective. Their efforts have resulted in obtaining early and broad payer coverage and inclusion in major provider pathways so that nearly all eligible patients are now have access to RevTropin. Within two weeks of approval, we obtained a preferred category one recommendation in the NCCN guidelines for the Reftropik triplet and doublet as a second-line treatment option for HR-positive, HER2-negative, advanced breast cancer patients lacking a PIK3CA mutation. With this NCCN recommendation and the direct engagement of our team, and it has had with nearly all US payers over the past 18 months, 91% of US commercial and Medicare lives are in healthcare plans that cover Reftropik. Given the complexity of managing care for cancer patients, most healthcare providers adhere to treatment guidelines, most commonly referred to as treatment pathways, that provide guidance and recommendations for the physicians who work within a specific healthcare system or network. Inclusion in these pathways eliminates a critical potential barrier to physician utilization of a medicine, and this process can take, in some cases, up to 12 months. Our team, though, was able to get Revtripic Incorporated in three of the four largest healthcare provider pathways within just 30 days of becoming commercially available. And these results reflect the groundwork we've been laying for the past 24 months. During this period, we've engaged over 1,000 key opinion leaders and community breast cancer experts, key accounts, major oncology organizations, including GPOs, state societies, and special interest groups, as well as patient advocacy groups. Our unbranded marketing campaign at PAMPathway.com drove awareness of the PAM pathway with metrics that tracked well ahead of industry benchmarks. CME and third-party peer-to-peer programs and regional events have further increased levels of awareness about the importance of comprehensive PAM inhibition and the unmet need in the second-line setting. With the build-out of the commercialization infrastructure needed to support the successful launch of RevTurbPIC completed, commercial launch activities for RevTurbPIC commenced immediately after approval. Our 88 oncology sales specialists who have an average of 24 years of industry experience, are calling on physicians, supporting installation of RevTorPIC order sets within the electronic health record systems of their accounts, and in servicing infusion centers and pharmacies. Our strategic accounts, payer reimbursement, medical science liaison, and KOL focused teams are following through on the groundwork they laid prior to RevTorPIC approval. All of these efforts are designed to offer patients and providers with rapid access and seamless support. to enable treating physicians to obtain, get it solicited on behalf of their eligible patients after we received FDA approval and prior to commercial availability of RevTroPIC. So, Acuity opened an expanded access program in mid-August. And now, nearly all of the patients enrolled in this program have been transitioned to commercial product. Shipments of RevTroPIC, which began on September 30th, at a wholesale acquisition cost of for $10,000 per vial, or $30,000 per 28-day cycle of treatment. Published epidemiological data estimates there are 37,000 patients in the U.S. receiving second-line treatment for HR-positive HER2-negative advanced breast cancer, and that based on the data from the VICTORIA-1 trial, patients treated with the gadathelosib regimen in this setting will remain on therapy for an average of 10 treatment cycles. Assuming net receipt of 80% of our $30,000 WAC price per cycle, We estimate the total addressable market for Revtropik in the second line setting, including both PIK3CA wild type and mutant patients, is approximately $9 billion annually. Most healthcare providers will order Revtropik through specialty distributors using buy and bill reimbursement. Revtropik is then drop shipped directly to the treatment location, which is typical for infused therapies, rather than through specialty pharmacies. By selling the product through this channel, We do not obtain access to granular information such as the number of doctors prescribing or the number of patients receiving Rift or Pick. As a result, when we report sales results beginning next year, the data we will be able to provide will be limited to metrics such as gross and net sales, file shift, and market access related metrics. We expect to provide a flash report on fourth quarter sales in mid-January, and we look forward to providing further updates next year. I'd like now to turn to an update on the status of our clinical development programs and recently reported data. Based on the positive data from the PIK3CA mutant cohort of the Phase 3 Victoria 1 study, we submitted a supplemental NDA to the FDA in the third quarter of 2026, and we expect to submit Victoria 1 Phase 3 data for both the wild-type and mutant cohorts to global regulatory authorities later this year or early next year. In October, updated results from the Phase III Victoria I study were presented in a late-breaking rapid oral presentation at ESMO. The key results included medium PFS of 21.5 months with the getotelicib triplet and 11.5 months with the getotelicib doublet versus 9.1 months with opalypsib plus fluvestrin in patients who had no liver metastases. The hazard ratio for the getotelicib triplet and doublet versus the opalypsib doublet was 0.46 and 0.71, respectively. And this is a particularly important result, since patients lacking liver mets represent approximately 70% of all patients treated in the setting, according to real-world analyses. Now, results for patients with liver mets were also very favorable and consistent with the primary PFS analysis. But again, it's less of triplet and doublet versus the epilepsy of doublet. The hazard ratio was 0.47 and 0.38, respectively. The objective response rate for patients with a valuable disease, updated to include both confirmed and unconfirmed responders, was 59% and 43% for the Gettys-Lissab triplet and doublet, respectively, versus 33% for the opalypsib doublet. And for these patients, the median duration of response for the Gettys-Lissab triplet and doublet was 19.4 and 27.8 months, respectively, versus 7.5 months for opalypsib plus fulvestrin. The discontinuation rate for gadotilisib due to adverse events was 5% and 4%, with the gadotilisib triplet and doublet, respectively, compared to 19% for opalipsib plus fulvestrin. The gadotilisib treatment discontinuation rate for the mutant cohort was lower than was reported for the wild-type cohort. The higher discontinuation rate for the wild-type cohort versus the mutant cohort largely reflects the activity in one region early in the study that enrolled a significant proportion of patients in the first six months. Discontinuations fell in this region as physicians gained experience. Since a much larger proportion of wild-type patients were enrolled during this period than mutant patients, the impact of this initial higher discontinuation rate early in the study fell disproportionately on the wild-type cohort. In the mutant cohort, which enrolled more slowly initially and over a longer period of time than the wild-type cohort, we did not see disparity in discontinuation rates across regions. Thus, we believe the treatment discontinuation rate for getotelicib reported for the mutant cohort to 4% to 5%. This represents what we expect to see in a real-world setting. And consistent with the data from the PIK3Ci wild-type cohort, the stomatitis events observed occurred primarily in the first cycle and were transient. By the second cycle of treatment, less than 3% of patients had grade 3 stomatitis, and all grade 3 events improved within one to two weeks. Discontinuations due to stomatitis for the gadotelicid triplet doublet were minimal, 1% and 0%, respectively. Additionally, at ESMO, Dr. Sarah Tulaney, Chief of the Division of Breast Oncology at the Dana-Farber Cancer Institute, presented a comparative analysis of data for the gadotelicib regimens from the PIK3CA wild-type cohort of VICTORIA-1 and other regimens evaluated in patients with HR-positive or T-negative advanced breast cancer. Eight studies were included in this network meta-analysis, comparing progression-free survival outcomes in randomized controlled trials of systemic treatments evaluated among patients with HR-positive HER2-negative breast cancer who had prior CDK4-6 exposure and had PIK3CA wild-type tumors. And this analysis found that the gadot-solicib triplet and doublet each demonstrated statistically significant or numerically superior improvement in PFS and a progression-free survival rate at six months relative to all of the non-gadot-solicib regimens evaluated. Of note, the analysis found that patients treated with the gadot-solicib triplet and doublet were two times more likely and 1.5 1.5 times more likely, respectively, at a statistically significant level to survive without disease progression or death compared to ImluNestrin plus Abdomen and Cyclob. We expect to provide further updates to results from both the mutant and wild type cohorts in Victoria 1 at the upcoming San Antonio Breast Cancer Symposium later this year. The guided solicit regimens have now demonstrated the potential to improve the standard of care in the second line setting regardless of the PIK3CA status of a patient's tumor. and we believe the results from the VICTORIA-1 study validate our pioneering approach to targeting cancers involving the PI3K, AKT, mTOR or PAM pathway. Additionally, these results augur well for the Phase 3 VICTORIA-2 trial we have underway to advance development of getotelicib for two different HR-positive for two negative advanced breast cancer populations in the first-line setting. Results from our Phase 1B clinical trial provided strong evidence that the PAM pathway is an important disease driver in treatment-naive patients with advanced breast cancer. In the early phase one study, we evaluated Getiflicid plus Pavaciclib and Lectrozole as first-line treatment in 41 patients with endocrine-sensitive, HR-positive, HER2-negative advanced breast cancer. Median PFS was 48.6 months, which compares favorably to historical data of approximately 25 months for Rivociclib plus Lectrozole, the therapy we are using as the control in our Victoria 2 trial. The objective response rate was 79% for the gadotelicid triplet, which again compares favorably to historical data of 53% for rivocyclib plus letrozole. In light of the positive results for the PIK3CA wild type of mutant cohorts in Victoria 1 and the promising preliminary data for a gadotelicid triplet as first-line treatment, we're optimistic about the results of both the first-line studies. In successful development in the first-line setting, would offer the potential to advance the standard of care for the approximately 90,000 women each year who are diagnosed with late-stage HR-positive HER2-negative advanced breast cancer in the U.S., irrespective of their endocrine sensitivity or PIK3CA status. The total addressable market for getotelicib in the first-line setting is well over $10 billion annually. Our advancement of a subcutaneous getotelicib formulation is ongoing with the goal of demonstrating clinical equivalence to the current intravenous formulation of getotelicib. Subcutaneous formulation is aimed to support potential future indications for Gettysilicib regimens that may result in duration of treatment periods greater than several years. I'd like now to turn to our Phase 1V2 clinical trial. That's evaluating Gettysilicib in combination with Duralutamide in men with metastatic castration-resistant prostate cancer. So, Acuity presented updated data from this study during a poster session at last month's ESMO Congress in 2026. Key results included Median progression-free survival, or RPFS, was 15.7 months, and the six-month RPFS rate was 82.2% in patients with prior exposure to ibuprofen. Median PFS was 9.1 months, and the six-month RPFS rate was 62.5% in patients with prior exposure to enzalotamide. Both sets of results compare favorably to published data for patients with either a novel hormonal therapy or docetaxel in this setting. Now the difference in results between patients with prior exposure to abiraterone versus enzalatamide was expected and reflects differences in the mechanism of action of these two drugs. For patients who had more than 50% decreases from baseline PSA, we observed them consistently across all dose levels. PSA response rates were 36%, 47%, and 67%. at the 120, 180, and 240 milligram dose levels, respectively, in patients with prior exposure to either abiturone or enzalatomate. Geta-Felicibusteroleutalyte demonstrated a manageable safety profile across the evaluated dose levels of 120, 180, and 240 mg with only one dose limiting toxicity, which was grade 3 rash. no grade four or five treatment-related adverse events or TRIEs and no TRIEs leading to discontinuation of GETA or death. Grade three TRIEs occurred in 20% of patients with only rash and varitis occurring in more than one patient. A randomized phase two study to determine the recommended phase three dose level of gadotilicib in combination with darolutamide in patients with metastatic castration-resistant prostate cancer is expected to begin in the first half of 2027 after completion of the phase 1b part of this study. Now with programs in both breast cancer and prostate cancer reflecting the important role of the PAN pathway in these diseases, CellCurity is well positioned to build an important pharmaceutical company over the next few years. And that concludes my remarks. I would like now to hand the call over to Vicky, our CFO, to review our finances.

Want transcripts like this in your own app? Try the Earnings call API, or read the transcript API docs.

Disclaimer

This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.

-

-

Use this data in your own app

Pull this call's transcript, audio and slides with the Earnings call transcripts API.

See pricing

9,000+ companies · REST API